GCTKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Glucotrack, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.68−0.04 (-5.56%)
Close on Oct 19, 2026
- Market cap
- $3.43M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Glucotrack, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Europe [Member] | $208.46K | $41.49K | $504.19K | $431.77K | $13.42K | $32.00K | 100.2% | +402.5% |
| Asia and Pacific [Member] | $300 | $2.00K | $85.27K | $179.92K | $129.75K | $27.78K | 0.1% | -85.0% |
From the segment and revenue-disaggregation notes of Glucotrack's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.